- Home
- EQ vs MDIA Comparison
EQ vs MDIA Comparison
Compare EQ & MDIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- MDIA
- Stock Information
- Founded
- EQ 2017
- MDIA 2019
- Country
- EQ United States
- MDIA United States
- Employees
- EQ N/A
- MDIA N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- MDIA Broadcasting
- Sector
- EQ Health Care
- MDIA Consumer Discretionary
- Exchange
- EQ Nasdaq
- MDIA Nasdaq
- Market Cap
- EQ 85.1M
- MDIA 69.2M
- IPO Year
- EQ 2018
- MDIA N/A
- Fundamental
- Price
- EQ $1.34
- MDIA $1.26
- Analyst Decision
- EQ Hold
- MDIA
- Analyst Count
- EQ 2
- MDIA 0
- Target Price
- EQ $1.00
- MDIA N/A
- AVG Volume (30 Days)
- EQ 725.3K
- MDIA 138.7K
- Earning Date
- EQ 11-12-2025
- MDIA 11-13-2025
- Dividend Yield
- EQ N/A
- MDIA N/A
- EPS Growth
- EQ N/A
- MDIA N/A
- EPS
- EQ N/A
- MDIA 0.40
- Revenue
- EQ $16,553,000.00
- MDIA $121,938,000.00
- Revenue This Year
- EQ N/A
- MDIA N/A
- Revenue Next Year
- EQ N/A
- MDIA N/A
- P/E Ratio
- EQ N/A
- MDIA $3.07
- Revenue Growth
- EQ N/A
- MDIA 165.75
- 52 Week Low
- EQ $0.27
- MDIA $0.79
- 52 Week High
- EQ $2.35
- MDIA $2.28
- Technical
- Relative Strength Index (RSI)
- EQ 43.10
- MDIA 44.59
- Support Level
- EQ $1.41
- MDIA $1.20
- Resistance Level
- EQ $1.64
- MDIA $1.29
- Average True Range (ATR)
- EQ 0.11
- MDIA 0.04
- MACD
- EQ -0.02
- MDIA -0.00
- Stochastic Oscillator
- EQ 9.11
- MDIA 37.50
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.